Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 10Neoplasms 9Carcinoma 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasm Metastasis 3Melanoma 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Lung Neoplasms 2Kidney Diseases 2Glioblastoma 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2cT2a N0NxM0 Renal Tumor 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors 1Solid Malignancies 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Refractory or Recurrent Solid Tumors, Excluding CNS Tumors 1Prostatic Neoplasms 1

Interventions

Sunitinib 4Nivolumab 4pazopanib 3Radiosurgery 3Ipilimumab 3Radiopharmaceuticals 1Molecular Imaging 1Interleukin-2 1Everolimus 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Clear-cell metastatic renal cell carcinoma × Axitinib × Clear all
NCT01693822 2024-11-21

A-PREDICT

Institute of Cancer Research, United Kingdom

Phase 2 Completed
65 enrolled 15 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡